Developer docs
API playgroundTry for free, no card

Search company profiles

Lumicell

Full company profile

uuid0000avw

Namestring
Lumicell
Legal namestring
Lumicell Inc.
Websiteurl
lumicell.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Lumicell is a privately held clinical-stage-turned-commercial medical technology company headquartered in Waltham, Massachusetts, developing fluorescence-guided imaging systems for the intraoperative detection of residual cancer. Its commercial product, LumiSystem, is the first FDA-approved drug-device combination for breast cancer lumpectomy — combining LUMISIGHT (pegulicianine), a tumor-activated fluorescent prodrug cleaved by cathepsins and matrix metalloproteases overexpressed in malignant tissue, with the Lumicell Direct Visualization System (DVS), a handheld imaging probe that scans the lumpectomy cavity in real time. The system demonstrated 84% diagnostic accuracy in the INSITE pivotal trial (published in NEJM Evidence) and is designed to reduce the approximately 36% re-excision rate caused by positive or falsely negative margins in breast-conserving surgery.

The company sells LumiSystem to U.S. hospital outpatient departments and cancer centers via a direct enterprise sales motion led by a Chief Commercial Officer, with initial commercial use at Stanford Healthcare and expansion targeted at other academic medical centers. Reimbursement is enabled by permanent HCPCS code A9615 for the imaging agent, CPT Category III code 0945T for the procedure, and CMS transitional pass-through payments, generating a hybrid revenue model of capital equipment (DVS console), consumables (single-use probe covers), and per-injection pharmaceutical revenue. Cumulative funding exceeds $250 million across equity rounds, NIH/SBIR grants, and a recent $12M SEC-registered offering, with Intuitive Venture Partners as a notable strategic investor alongside Kodiak Venture Partners, BlueIO, Rivas Capital, Launch Capital, and Reverse-Entropy Ventures.

Beyond breast cancer, Lumicell is extending its platform across multiple solid tumor indications (gastrointestinal, peritoneal metastases, brain, sarcoma, prostate, esophageal) and is developing a novel flexible endoscopic platform for Barrett's esophagus detection under a $400K NCI SBIR grant. The company collaborates with MGH on GI programs and with Stand Up To Cancer/Cancer Research UK on a multi-country gastric cancer endoscopy trial spanning the U.S., U.K., and South Korea, signaling both vertical and geographic pipeline expansion.

Short descriptiontext

Lumicell is a commercial-stage medical technology company that sells LumiSystem, the first FDA-approved fluorescence-guided drug-device combination enabling real-time intraoperative detection of residual breast cancer during lumpectomy, targeting hospital outpatient departments and academic cancer centers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersWaltham, United States
HQ citystring
Waltham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
fluorescence-guided surgery, intraoperative cancer imaging, optical imaging agents, breast cancer detection, surgical oncology devices
Industry2 codes
PRIMARYHLAHADAH
Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAGAIAE
Microscopy, Imaging & Flow Cytometry Instruments
NAICS code3 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical Appliance and Supplies Manufacturing339113
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code3 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Pharmaceutical Preparations2834
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Surgical Oncology Imaging
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1LUMISIGHT (pegulicianine) Optical Imaging Agent
TypeHardware Sales
Description

Sale of pegulicianine as a pharmaceutical optical imaging agent to hospital outpatient departments for use during lumpectomy surgery. CMS granted transitional pass-through (TPT) payment (HCPCS code C9171, transitioning to permanent A9615) effective October 1, 2024, under the hospital outpatient prospective payment system (OPPS).

lumicell.com
2Lumicell DVS Device System
TypeHardware Sales
Description

The Lumicell Direct Visualization System (DVS) handheld probe and console sold to hospital surgical departments. Includes a reusable probe and single-use sterile probe covers, generating recurring consumable revenue.

lumicell.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Pricing details2 tiers
1LUMISIGHT (pegulicianine) optical imaging agent - priced per mg injection under HCPCS code A9615
ModelUnit PricingBilling cadencePay-as-you-go
Notes

CMS transitional pass-through payment enables hospital outpatient billing. Specific patient or hospital pricing not publicly disclosed.

lumicell.com
2Lumicell DVS (handheld probe + console system) - capital equipment + consumable probe covers
ModelUnit PricingBilling cadenceMulti-year contract
Notes

DVS console and reusable probe sold as capital equipment; single-use sterile probe covers represent recurring consumable revenue. Pricing not publicly disclosed.

lumicell.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1LumiSystem
Description

The combination of LUMISIGHT (pegulicianine) optical imaging agent and Lumicell Direct Visualization System (DVS) for fluorescence-guided breast cancer surgery

lumicell.com
+2 more records
Core offering1 text field

Lumicell develops and commercializes LumiSystem, the first and only FDA-approved fluorescence-guided drug-device combination for real-time intraoperative detection of residual cancer during breast cancer lumpectomy surgery. LumiSystem pairs LUMISIGHT (pegulicianine), an optical imaging prodrug that fluoresces when cleaved by tumor-overexpressed cathepsins and matrix metalloproteases, with the Lumicell Direct Visualization System (DVS), a handheld imaging probe for in-cavity scanning. The technology is also being extended across additional solid tumor indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 84% diagnostic accuracy in detecting residual breast cancer during lumpectomy (INSITE pivotal trial, NEJM Evidence 2023)
+3 more records
Product overview1 text field

Lumicell offers the LumiSystem, a drug-device combination product comprising two FDA-approved components: LUMISIGHT (pegulicianine), an optical imaging agent/prodrug, and the Lumicell Direct Visualization System (DVS), a handheld fluorescence imaging device. Together, they enable real-time intraoperative detection of residual breast cancer during lumpectomy surgery with 84% diagnostic accuracy. The system is the first and only FDA-approved fluorescence-guided imaging technology for breast cancer detection and is also being explored for additional solid tumor indications including gastrointestinal cancers, peritoneal metastases, brain cancer, sarcoma, and prostate cancer.

Product and service3 records
1LumiSystem
CategoryDrug-Device Combination Product
Description

LumiSystem is the first and only FDA-approved fluorescence-guided drug-device combination for breast cancer surgery. It combines the LUMISIGHT optical imaging agent with the Lumicell DVS device to enable real-time detection of residual cancer within the breast cavity during lumpectomy surgery, achieving 84% diagnostic accuracy. It is intended for breast surgeons and surgical oncologists at hospital outpatient departments and cancer centers.

2LUMISIGHT (pegulicianine)
CategoryOptical Imaging Agent / Pharmaceutical
Description

LUMISIGHT is an FDA-approved optical imaging agent (prodrug) that fluoresces at sites of suspected cancerous tissue. It is optically inactive when intact and produces a fluorescent signal after its peptide chain is cleaved by cathepsins and matrix metalloproteases (MMPs), enzymes that are elevated in and around tumor tissue. It is administered to patients undergoing breast cancer lumpectomy surgery.

3Lumicell Direct Visualization System (DVS)
CategoryMedical Imaging Device
Description

The Lumicell Direct Visualization System (DVS) is an FDA-approved fluorescence imaging device that provides real-time visualization of cancer inside the breast cavity. The handheld probe scans the lumpectomy cavity following removal of the primary specimen to detect residual cancer via fluorescent signals from LUMISIGHT. It is intended for breast surgeons and surgical oncologists in hospital operating rooms.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-08
Description

SU2C and Cancer Research UK announced extended funding of $3 million for the SU2C Gastric Cancer Interception Dream Team to launch a clinical trial testing a novel fluorescence-guided endoscopy approach. Lumicell is supporting this initiative with an investigational device and new drug, collaborating with institutions in the US, UK, and South Korea to validate a blood biomarker (ORF1p) and expand early detection of gastric cancer.

2Learn Look Locate
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2025-12-19
Description

Lumicell announced a collaboration with Learn Look Locate to develop educational content about breast cancer surgery, including lumpectomy procedures and associated technology. The partnership produces patient-friendly educational materials and digital campaigns to improve awareness and understanding of advanced surgical technologies like LumiSystem, aiming to enhance patient education and awareness of breast cancer treatment innovations.

biospace.com
3Dr. Andrew T. Chan, MD, MPH and Dr. David A. Drew, Ph.D. (Massachusetts General Hospital)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-28
Description

Dr. Chan (Vice-chair of Research, Division of Gastroenterology, MGH) and Dr. Drew (Assistant Professor, MGH Clinical and Translational Epidemiology Unit) collaborated with Lumicell on a Phase I NIH SBIR to develop a novel flexible endoscopic platform for fluorescence imaging of LUMISIGHT to detect early esophageal lesions in Barrett's esophagus. Dr. Chan and Dr. Drew also led the first clinical trial of pegulicianine in gastrointestinal cancer patients, presenting compelling findings at AACR Annual Meeting 2025.

lumicell.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-30
Description

Lumicell awarded a Phase I NIH SBIR contract from the NCI to develop a novel flexible endoscopic platform combining far-red fluorescence and reflected light imaging to detect precancerous and early-stage esophageal adenocarcinoma under standard clinical endoscopy. Funding of approximately $400,000 with a one-year award period beginning September 2024.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Stryker acquired Novadaq and now markets the SPY-PHI fluorescence imaging platform for intraoperative perfusion and tissue assessment, making it the most direct large incumbent in fluorescence-guided surgery. Comparable to Lumicell in targeting intraoperative visualization during surgical procedures.

TypeDirect peer
Description

Karl Storz offers fluorescence endoscopy systems (e.g., ICG-based platforms) for minimally invasive and open surgery, directly competing with Lumicell's DVS in surgical imaging workflow and targeting similar OR customers.

TypeBroad incumbent
Description

Olympus provides endoscopic imaging platforms with integrated fluorescence modes (NBI, IR) used in surgical and GI applications. Comparable to Lumicell through overlap in intraoperative visualization and adjacent GI/endoscopy markets where LUMISIGHT is being expanded.

TypeDirect peer
Description

Bracco markets imaging agents such as Lumason (sulfur hexafluoride microbubbles) used in echocardiography and ultrasound imaging. Comparable to Lumicell as a contrast/imaging-agent company selling into hospitals and ambulatory surgery centers with established reimbursement infrastructure.

TypeBroad incumbent
Description

GE HealthCare is a broad medical imaging and diagnostics incumbent that develops contrast agents, imaging equipment, and surgical visualization tools. Comparable to Lumicell as a hospital imaging partner with overlapping surgical and diagnostic imaging customers.

TypeOthers
Description

Intuitive Surgical is the leading robotic-assisted surgery platform (da Vinci) and a strategic investor in Lumicell through Intuitive Venture Partners with board representation. Comparable as a strategic ecosystem partner whose installed base could distribute intraoperative imaging capabilities.

7OnLume
TypeEmerging player
Description

OnLume is an emerging fluorescence-guided surgery imaging company developing real-time surgical visualization systems. Comparable to Lumicell as a similarly sized fluorescence-guided surgery technology developer with overlapping target surgical use cases.

TypeBroad incumbent
Description

Guerbet is a global specialist in contrast media and imaging solutions for medical imaging (CT, MRI, interventional radiology). Comparable to Lumicell as a diagnostic imaging agent company with hospital-channel sales, regulatory expertise, and established payor relationships.

TypeOthers
Description

Revvity supplies imaging reagents, molecular probes, and life-science tools used in research and clinical diagnostics. Comparable to Lumicell in developing and commercializing fluorescence-based molecular imaging technologies, though with a broader life-science research focus.

TypeBroad incumbent
Description

Medtronic is a broad medical-device incumbent with surgical, imaging, and oncology-adjacent portfolios (e.g., Surgical Innovations, AIS). Comparable to Lumicell as a large hospital-channel partner with overlapping surgical oncology customer relationships and capital to acquire emerging intraoperative imaging technologies.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lumicell

Surgical Oncology Imaginglumicell.com

Lumicell is a commercial-stage medical technology company that sells LumiSystem, the first FDA-approved fluorescence-guided drug-device combination enabling real-time intraoperative detection of residual breast cancer during lumpectomy, targeting hospital outpatient departments and academic cancer centers.

What Lumicell does

Lumicell is a privately held clinical-stage-turned-commercial medical technology company headquartered in Waltham, Massachusetts, developing fluorescence-guided imaging systems for the intraoperative detection of residual cancer. Its commercial product, LumiSystem, is the first FDA-approved drug-device combination for breast cancer lumpectomy — combining LUMISIGHT (pegulicianine), a tumor-activated fluorescent prodrug cleaved by cathepsins and matrix metalloproteases overexpressed in malignant tissue, with the Lumicell Direct Visualization System (DVS), a handheld imaging probe that scans the lumpectomy cavity in real time. The system demonstrated 84% diagnostic accuracy in the INSITE pivotal trial (published in NEJM Evidence) and is designed to reduce the approximately 36% re-excision rate caused by positive or falsely negative margins in breast-conserving surgery.

The company sells LumiSystem to U.S. hospital outpatient departments and cancer centers via a direct enterprise sales motion led by a Chief Commercial Officer, with initial commercial use at Stanford Healthcare and expansion targeted at other academic medical centers. Reimbursement is enabled by permanent HCPCS code A9615 for the imaging agent, CPT Category III code 0945T for the procedure, and CMS transitional pass-through payments, generating a hybrid revenue model of capital equipment (DVS console), consumables (single-use probe covers), and per-injection pharmaceutical revenue. Cumulative funding exceeds $250 million across equity rounds, NIH/SBIR grants, and a recent $12M SEC-registered offering, with Intuitive Venture Partners as a notable strategic investor alongside Kodiak Venture Partners, BlueIO, Rivas Capital, Launch Capital, and Reverse-Entropy Ventures.

Beyond breast cancer, Lumicell is extending its platform across multiple solid tumor indications (gastrointestinal, peritoneal metastases, brain, sarcoma, prostate, esophageal) and is developing a novel flexible endoscopic platform for Barrett's esophagus detection under a $400K NCI SBIR grant. The company collaborates with MGH on GI programs and with Stand Up To Cancer/Cancer Research UK on a multi-country gastric cancer endoscopy trial spanning the U.S., U.K., and South Korea, signaling both vertical and geographic pipeline expansion.

Lumicell firmographics

Firmographics
Name
Lumicell
Legal name
Lumicell Inc.
Website
https://lumicell.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
51–100 employees
Short description
Lumicell is a commercial-stage medical technology company that sells LumiSystem, the first FDA-approved fluorescence-guided drug-device combination enabling real-time intraoperative detection of residual breast cancer during lumpectomy, targeting hospital outpatient departments and academic cancer centers.
Ownership category
akta.pro rank

Lumicell industry classification

Industry
Product category
Surgical Oncology Imaging
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Surgical & Medical Instruments & Apparatus (3841), Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHADAH
Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAGAIAE
Microscopy, Imaging & Flow Cytometry Instruments

Keywords

  • Fluorescence-guided surgery
  • Intraoperative cancer imaging
  • Optical imaging agents
  • Breast cancer detection
  • Surgical oncology devices

Where Lumicell is headquartered

Location

Headquarters

HQ city
Waltham
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Lumicell business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. LUMISIGHT (pegulicianine) Optical Imaging Agent: Sale of pegulicianine as a pharmaceutical optical imaging agent to hospital outpatient departments for use during lumpectomy surgery. CMS granted transitional pass-through (TPT) payment (HCPCS code C9171, transitioning to permanent A9615) effective October 1, 2024, under the hospital outpatient prospective payment system (OPPS).
  2. Lumicell DVS Device System: The Lumicell Direct Visualization System (DVS) handheld probe and console sold to hospital surgical departments. Includes a reusable probe and single-use sterile probe covers, generating recurring consumable revenue.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goLUMISIGHT (pegulicianine) optical imaging agent - priced per mg injection under HCPCS code A9615
Unit PricingMulti-year contractLumicell DVS (handheld probe + console system) - capital equipment + consumable probe covers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels8 records

Lumicell product offering

Product offering

Core offering

Lumicell develops and commercializes LumiSystem, the first and only FDA-approved fluorescence-guided drug-device combination for real-time intraoperative detection of residual cancer during breast cancer lumpectomy surgery. LumiSystem pairs LUMISIGHT (pegulicianine), an optical imaging prodrug that fluoresces when cleaved by tumor-overexpressed cathepsins and matrix metalloproteases, with the Lumicell Direct Visualization System (DVS), a handheld imaging probe for in-cavity scanning. The technology is also being extended across additional solid tumor indications.

Product overview

Lumicell offers the LumiSystem, a drug-device combination product comprising two FDA-approved components: LUMISIGHT (pegulicianine), an optical imaging agent/prodrug, and the Lumicell Direct Visualization System (DVS), a handheld fluorescence imaging device. Together, they enable real-time intraoperative detection of residual breast cancer during lumpectomy surgery with 84% diagnostic accuracy. The system is the first and only FDA-approved fluorescence-guided imaging technology for breast cancer detection and is also being explored for additional solid tumor indications including gastrointestinal cancers, peritoneal metastases, brain cancer, sarcoma, and prostate cancer.

Differentiator

Problem solved

Functional benefit

Brands

  • LumiSystem: The combination of LUMISIGHT (pegulicianine) optical imaging agent and Lumicell Direct Visualization System (DVS) for fluorescence-guided breast cancer surgery
  • LUMISIGHT
  • Lumicell DVS

Products and services

  • LumiSystem LumiSystem is the first and only FDA-approved fluorescence-guided drug-device combination for breast cancer surgery. It combines the LUMISIGHT optical imaging agent with the Lumicell DVS device to enable real-time detection of residual cancer within the breast cavity during lumpectomy surgery, achieving 84% diagnostic accuracy. It is intended for breast surgeons and surgical oncologists at hospital outpatient departments and cancer centers.
  • LUMISIGHT (pegulicianine) LUMISIGHT is an FDA-approved optical imaging agent (prodrug) that fluoresces at sites of suspected cancerous tissue. It is optically inactive when intact and produces a fluorescent signal after its peptide chain is cleaved by cathepsins and matrix metalloproteases (MMPs), enzymes that are elevated in and around tumor tissue. It is administered to patients undergoing breast cancer lumpectomy surgery.
  • Lumicell Direct Visualization System (DVS) The Lumicell Direct Visualization System (DVS) is an FDA-approved fluorescence imaging device that provides real-time visualization of cancer inside the breast cavity. The handheld probe scans the lumpectomy cavity following removal of the primary specimen to detect residual cancer via fluorescent signals from LUMISIGHT. It is intended for breast surgeons and surgical oncologists in hospital operating rooms.

Quantifiable outcome

  • 84% diagnostic accuracy in detecting residual breast cancer during lumpectomy (INSITE pivotal trial, NEJM Evidence 2023)
  • +3 more outcomes

Companies that use Lumicell

Customer profile

Named customers5 records

Segments2 records

Ideal customer profiles1 record

Lumicell technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Lumicell partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Stand Up To Cancer (SU2C) and Cancer Research UKcoreStrategic or Co-development Partner · 8 January 2026SU2C and Cancer Research UK announced extended funding of $3 million for the SU2C Gastric Cancer Interception Dream Team to launch a clinical trial testing a novel fluorescence-guided endoscopy approach. Lumicell is supporting this initiative with an investigational device and new drug, collaborating with institutions in the US, UK, and South Korea to validate a blood biomarker (ORF1p) and expand early detection of gastric cancer.
  • Learn Look LocateminorGTM or Marketing Partner · 19 December 2025Lumicell announced a collaboration with Learn Look Locate to develop educational content about breast cancer surgery, including lumpectomy procedures and associated technology. The partnership produces patient-friendly educational materials and digital campaigns to improve awareness and understanding of advanced surgical technologies like LumiSystem, aiming to enhance patient education and awareness of breast cancer treatment innovations.
  • Dr. Andrew T. Chan, MD, MPH and Dr. David A. Drew, Ph.D. (Massachusetts General Hospital)coreStrategic or Co-development Partner · 28 April 2025Dr. Chan (Vice-chair of Research, Division of Gastroenterology, MGH) and Dr. Drew (Assistant Professor, MGH Clinical and Translational Epidemiology Unit) collaborated with Lumicell on a Phase I NIH SBIR to develop a novel flexible endoscopic platform for fluorescence imaging of LUMISIGHT to detect early esophageal lesions in Barrett's esophagus. Dr. Chan and Dr. Drew also led the first clinical trial of pegulicianine in gastrointestinal cancer patients, presenting compelling findings at AACR Annual Meeting 2025.
  • National Cancer Institute (NCI) / National Institutes of Health (NIH)coreStrategic or Co-development Partner · 30 September 2024Lumicell awarded a Phase I NIH SBIR contract from the NCI to develop a novel flexible endoscopic platform combining far-red fluorescence and reflected light imaging to detect precancerous and early-stage esophageal adenocarcinoma under standard clinical endoscopy. Funding of approximately $400,000 with a one-year award period beginning September 2024.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Lumicell competitors and assessment

Company assessment

Broad incumbents

  • Stryker: Stryker acquired Novadaq and now markets the SPY-PHI fluorescence imaging platform for intraoperative perfusion and tissue assessment, making it the most direct large incumbent in fluorescence-guided surgery. Comparable to Lumicell in targeting intraoperative visualization during surgical procedures.
  • Olympus Corporation: Olympus provides endoscopic imaging platforms with integrated fluorescence modes (NBI, IR) used in surgical and GI applications. Comparable to Lumicell through overlap in intraoperative visualization and adjacent GI/endoscopy markets where LUMISIGHT is being expanded.
  • GE HealthCare: GE HealthCare is a broad medical imaging and diagnostics incumbent that develops contrast agents, imaging equipment, and surgical visualization tools. Comparable to Lumicell as a hospital imaging partner with overlapping surgical and diagnostic imaging customers.
  • Guerbet: Guerbet is a global specialist in contrast media and imaging solutions for medical imaging (CT, MRI, interventional radiology). Comparable to Lumicell as a diagnostic imaging agent company with hospital-channel sales, regulatory expertise, and established payor relationships.
  • Medtronic: Medtronic is a broad medical-device incumbent with surgical, imaging, and oncology-adjacent portfolios (e.g., Surgical Innovations, AIS). Comparable to Lumicell as a large hospital-channel partner with overlapping surgical oncology customer relationships and capital to acquire emerging intraoperative imaging technologies.

Direct peers

  • Karl Storz: Karl Storz offers fluorescence endoscopy systems (e.g., ICG-based platforms) for minimally invasive and open surgery, directly competing with Lumicell's DVS in surgical imaging workflow and targeting similar OR customers.
  • Bracco Imaging: Bracco markets imaging agents such as Lumason (sulfur hexafluoride microbubbles) used in echocardiography and ultrasound imaging. Comparable to Lumicell as a contrast/imaging-agent company selling into hospitals and ambulatory surgery centers with established reimbursement infrastructure.

Others

  • Intuitive Surgical: Intuitive Surgical is the leading robotic-assisted surgery platform (da Vinci) and a strategic investor in Lumicell through Intuitive Venture Partners with board representation. Comparable as a strategic ecosystem partner whose installed base could distribute intraoperative imaging capabilities.
  • Revvity (formerly PerkinElmer Life Sciences): Revvity supplies imaging reagents, molecular probes, and life-science tools used in research and clinical diagnostics. Comparable to Lumicell in developing and commercializing fluorescence-based molecular imaging technologies, though with a broader life-science research focus.

Emerging players

  • OnLume: OnLume is an emerging fluorescence-guided surgery imaging company developing real-time surgical visualization systems. Comparable to Lumicell as a similarly sized fluorescence-guided surgery technology developer with overlapping target surgical use cases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Lumicell social profiles

Digital presence

Lumicell compliance and trust

Trust signal

Compliance1 record

Lumicell financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lumicell leadership team

Management profile

Number of profiles

Profiles10 records

Lumicell funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lumicell M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lumicell

What does Lumicell do?

Lumicell develops and commercializes LumiSystem, the first and only FDA-approved fluorescence-guided drug-device combination for real-time intraoperative detection of residual cancer during breast cancer lumpectomy surgery. LumiSystem pairs LUMISIGHT (pegulicianine), an optical imaging prodrug that fluoresces when cleaved by tumor-overexpressed cathepsins and matrix metalloproteases, with the Lumicell Direct Visualization System (DVS), a handheld imaging probe for in-cavity scanning. The technology is also being extended across additional solid tumor indications.

Is Lumicell a public or private company?

Lumicell is a private company. It is classified as venture growth investor backed and is currently operating.

When was Lumicell founded?

Lumicell was founded in 2012. It employs 51 to 100 people.

Where is Lumicell based?

Lumicell is headquartered in Waltham, United States, in the North America region.

How does Lumicell make money?

Two revenue lines are on record. LUMISIGHT (pegulicianine) Optical Imaging Agent is the primary driver. The others are lumicell DVS Device System.

Who are Lumicell's main competitors?

Broad incumbents on record are Stryker, Olympus Corporation, GE HealthCare, Guerbet and Medtronic. Direct peers are Karl Storz and Bracco Imaging. Others are Intuitive Surgical and Revvity (formerly PerkinElmer Life Sciences). OnLume is listed as an emerging player.

Does Lumicell have an API?

No public API is recorded for Lumicell.

What industry is Lumicell in?

Lumicell's product category is Surgical Oncology Imaging. Its primary akta.pro industry code is HLAHADAH, Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence), with a secondary code of HLAGAIAE, Microscopy, Imaging & Flow Cytometry Instruments. Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
OncLiveFDA Approves Lumisight and Lumicell DVS for Residual Breast Cancer DetectionThe FDA has approved the optical imaging agent Lumisight and the Lumicell Direct Visualization System for intraoperative detection of residual breast cancer tissue during lumpectomy surgery. Clinical data demonstrated an 84% diagnostic accuracy, with the system identifying residual disease in patients where standard pathology failed to detect it, potentially avoiding additional surgeries.B2B SaaS BlogLumicell Revenue 2025: $8.8M ARR (Bootstrapped)Lumicell, a biotechnology company based in Newton, Massachusetts, reported $8.8 million in annual recurring revenue for 2025. The company has remained bootstrapped since its founding in 2008, growing to a team of approximately 51 employees without raising external venture capital.Tracxn2026 Funding Rounds & List of InvestorsThe article presents a tabular list of funding rounds for Lumicell Diagnostics, detailing dates, amounts, and valuations from 2010 to 2025. It includes specific data points such as a Series D round in April 2025 and various other financing activities. The content serves as a historical record of the company's capital raising efforts.citybizLumicell Promotes Marnie Curbow to Chief Commercial OfficerLumicell has promoted Marnie Curbow to Chief Commercial Officer to oversee sales, marketing, and reimbursement as it expands the deployment of its FDA-approved fluorescence-guided cancer imaging system in U.S. hospitals. Curbow, who joined Lumicell in October 2025, will lead commercial operations while the company scales adoption of its technology for identifying residual cancer tissue during lumpectomy procedures. This appointment supports Lumicell's broader growth phase following its April 2024 regulatory approval.PR NewswireLumicell Promotes Marnie Curbow as Chief Commercial Officer to Drive Next Phase of GrowthLumicell, Inc., a Waltham, Massachusetts-based medical technology company, announced the promotion of Marnie Curbow to Chief Commercial Officer, effective immediately. Curbow, who joined the company in October 2025 as Vice President of Sales, has built Lumicell's commercial team and advanced its go-to-market strategy for its FDA-approved fluorescence-guided surgery platform designed to improve cancer detection during lumpectomy procedures.BioSpaceLumicell Promotes Marnie Curbow as Chief Commercial Officer to Drive Next Phase of GrowthLumicell promoted Marnie Curbow to Chief Commercial Officer, effective immediately. She previously served as Vice President of Sales and has built the company's commercial team. The promotion aims to drive growth for its FDA-approved fluorescence-guided surgery platform.BioSpaceLumicell Showcases Expanded Scientific and Clinical Engagement at ASBrS 2026 Annual MeetingLumicell announced an expanded presence at ASBrS 2026, featuring hands-on demonstrations of its LumiSystem, scientific data presentations, and educational sponsorships. The company will host a poster session on fluorescence-guided lumpectomy evaluation and sponsor the Fellows Course. Its booth is at #423, with clinical dinner programs.PR NewswireLumicell Showcases Expanded Scientific and Clinical Engagement at ASBrS 2026 Annual MeetingLumicell announced its expanded presence at the American Society of Breast Surgeons (ASBrS) 2026 Annual Meeting held April 29–May 3, 2026, at the Seattle Convention Center, featuring hands-on technology demonstrations and scientific presentations. The company will demonstrate its LumiSystem, designed to illuminate suspected residual cancer in the breast cavity following lumpectomy, host clinical dinner programs, and sponsor the ASBrS Fellows Course for surgical education. Lumicell's FDA-approved fluorescence imaging technology is being showcased to engage directly with the breast surgery community and advance intraoperative cancer detection.PR NewswireLumicell Featured on Health Uncensored with Dr. Drew to Discuss Advances in Breast Cancer SurgeryLumicell announced it will be featured on Health Uncensored with Dr. Drew on Fox Business on April 19th to discuss advances in its fluorescence-guided imaging technology for breast cancer surgery. The segment highlights how Lumicell's FDA-approved DVS system helps surgeons detect residual cancer during lumpectomy procedures, potentially reducing the need for additional surgeries. The program features the company's Chief Scientific Officer and a breast cancer patient who used the LumiSystem.openPR.comOverview of Segmentation, Market Dynamics, and Competitive Landscape in the Coronary Pressure MarketThe coronary pressure device market is projected to grow from $17.38 billion in 2024 to $30.38 billion by 2030 at a 9.7% compound annual growth rate, driven by wearable technology advancements, homecare adoption, and preventive cardiology initiatives. A significant industry move occurred in May 2024 when Johnson & Johnson Services Inc. acquired Shockwave Medical Inc., a US-based coronary pressure device provider, to strengthen its cardiovascular portfolio and expand treatment options. The article also notes that Lumicell, a US biotechnology firm, secured a $400,000 Phase I SBIR grant from the National Cancer Institute in October 2024 to develop a flexible endoscope for diagnosing Barrett's esophagus.